+499.5%
MRNA vs VRSK
-30.3%
+529.7%
-34.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | VRSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.2% | -2.5% | +0.3% | -0.6% |
| 7D | +5.5% | -3.1% | +8.6% | +7.7% |
| 30D | +158.7% | -1.6% | +160.3% | +156.5% |
| 3M | +182.1% | +3.5% | +178.6% | +176.0% |
| 6M | +151.8% | -13.4% | +165.2% | +158.7% |
| YTD | +393.6% | -16.5% | +410.1% | +417.2% |
| 1Y | +499.5% | -30.6% | +530.0% | +572.3% |
| All | +499.5% | -30.3% | +529.7% | +572.3% |
Cumulative growth
Daily Returns
Daily percentage return beside VRSK.
Daily Out/Under-Performance
Portfolio return minus VRSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × VRSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded VRSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling